Skip to content
Syenza News
  • Innovative Tech
  • Diseases
  • Health Policy
  • HTA
  • Data Analysis
  • Clinical Practice
  • Contributors
BACK TO MAIN SITE

Zambia’s National Health Insurance Making...

By Staff Writer

April 17, 2023

Chronic Heart Failure: PBAC Recommends Empagliflozin
Global Pull Incentive Needed to Future-Proof Antibiotic Innovation, Says OHE ...
Medscheme released updated MEDICINE EXCLUSION LIST APRIL 2023
Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in b...
Did CVDs recover post COVID-19 ?
Boosting local medicine production in Uganda: How import fees are affecting t...
Multiple myeloma is the second most common type of blood cancer, with approxi...
The evidence for Cannabidiol is building
HTA must consider health equity for progress
Mobocertinib added in NICE guidelines
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Eval...
Examining medicine shortages and their consequences through economic, clinica...
« Previous 1 … 13 14 15 16 17 Next »

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
PARTNER WITH US
schedule a meeting

SPEAK WITH US

+1 617 219 9400

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

WRITE US

inquiry2023@syenza.com

JOIN NEWSLETTER

This is required.
This is required.
This is required.

SERVICES

  • HEOR
  • Global Market Access
  • Dynamic Intelligence
  • Glossary of Terms
  • Advanced Degrees

QUICK LINKS

  • About
  • Case Studies
  • Insights
  • Art of Science
  • Careers
  • Contact Us
  • Copyright Notice
  • Privacy Policy
  • Terms & Conditions
schedule a meeting
LINKEDIN
TWITTER
© 2025 Syenza™. All rights reserved.

Made with by Frogiez

schedule a meeting